Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dutch Defend Choice Of Amsterdam For EMA As Italy Tries To Shift Agency To Milan

Executive Summary

The Italian government has asked the Court of Justice of the EU to annul the decision to site the European Medicines Agency in Amsterdam and wants to move the agency instead to Milan. But the Dutch government insists that the selection process was “fair” and that the need for temporary premises had been made clear all along.

You may also be interested in...



EMA Queries Cost Of New Dutch HQ As Milan Steps Up Legal Fight

The Dutch government has insisted that the relocation of the European Medicines Agency to Amsterdam will go smoothly and that the agency’s permanent headquarters will be ready on time, despite an argument over the costs of the new premises and a renewed drive by Italy to have the EMA located in Milan.

MEPs To Visit Amsterdam To Check On EMA Relocation Progress

Members of the European Parliament are heading to the Netherlands to see whether the European Medicines Agency’s relocation process is going according to plan. The move follows Italian criticisms that the Dutch provided “incomplete” information about their readiness to host the agency.

EMA To Consult Staff On Relocation Plans Again As Brexit Time Pressure Mounts

The EMA is planning another survey to see how many of its staff are likely to follow it to Amsterdam, while the agency’s executive director says having to move into temporary premises while a permanent home is constructed is inconvenient but should allow core regulatory activities to be pursued.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS122439

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel